JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment
JC jesus coin in India for beginners  - Unlock Fast Profits with AI Investment

JC jesus coin in India for beginners - Unlock Fast Profits with AI Investment

₹1195

JC jesus coin in India for beginners ✌️【Fixed Income】✌️Start with ₹500 and enjoy consistent, high returns with smart investment strategies.

quantity
Add to Wishlist
Product Description

JC jesus coin in India for beginners ✌️【Fixed Income】✌️Start with ₹500 and enjoy consistent, high returns with smart investment strategies.

JC jesus coin in India for beginners ✌️【Fixed Income】✌️Start with ₹500 and enjoy consistent, high returns with smart investment strategies.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

JC jesus coin in India for beginners ✌️【Fixed Income】✌️Invest ₹500 to unlock consistent monthly returns. Start now for big rewards!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

JC jesus coin in India for beginners ✌️【Fixed Income】✌️₹500 to start, high returns to earn. Join now and watch your wealth increase!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

JC jesus coin in India for beginners ✌️【Fixed Income】✌️Begin investing today with ₹500 and achieve reliable, high returns every month.The underperformance persists despite a 22.JC jesus coin in India for beginners ✌️【Fixed Income】✌️Secure high monthly returns with a ₹500 investment. Start your wealth journey today!

Related Products